4.6 Article

Bleomycin treatment of A549 human lung cancer cells results in association of MGr1-Ag and caveolin-1 in lipid rafts

Journal

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biocel.2010.10.001

Keywords

A549; Bleomycin; Caveolin-1; MGr1-Ag; Senescence

Funding

  1. German Academic Exchange Service
  2. German Research Foundation
  3. Wilhelm Sander-Foundation

Ask authors/readers for more resources

Bleomycin treatment of A549 cells induces senescence rather than apoptosis, a more usual response of cancer cells to cytotoxic drugs. We have previously shown that upregulation of caveolin-1, the main structural component of caveolae, plays a key role in this process. In order to gain a better understanding of the molecular basis of this phenomenon, caveolin-1-enriched microdomains of untreated and bleomycin-treated growth-arrested A549 cells were analysed for differential protein expression using 2-D DICE followed by LC-MS/MS. One of these differentially expressed proteins was found to be the multidrug resistance-associated protein (MGr1-Ag). We show that MGr1-Ag becomes partly localised in lipid rafts following bleomycin treatment, and that MGr1-Ag and caveolin-1 occur in a common protein complex in vivo using co-immunoprecipitation studies. GST pull-down assays demonstrated an increased interaction between MGr1-Ag and caveolin-1 following bleomycin treatment in vitro. Our results reveal MGr1-Ag as a novel lipid raft protein; its increased association with caveolin-1 in bleomycin-induced cell cycle arrest and subsequent cellular senescence might contribute to the success of chemotherapy. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available